Showing 601 - 620 results of 1,061 for search '"lymphoma"', query time: 0.06s Refine Results
  1. 601
  2. 602
  3. 603

    Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells by Valentin P. Shichkin, Roman M. Moriev

    Published 2014-01-01
    “…Previously, the mouse A20 B-cell lymphoma engineered to express hemagglutinin (HA) antigen (A20HA) was used as a systemic tumor model. …”
    Get full text
    Article
  4. 604

    Clinical trial participation, clinical care, and patient outcomes by practice setting: a real-world database analysis of patients with Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma by Debora S. Bruno, Manoj Khanal, Xiaohong Li, Maricer P. Escalon, Katherine Winfree, Lisa M. Hess

    Published 2025-12-01
    “…Objective This study was designed to compare treatment patterns, clinical trial participation, and clinical outcomes among patients with small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) or Mantle cell lymphoma (MCL) by site of care.Methods A nationwide electronic health record (EHR)-derived de-identified database was utilized for this study. …”
    Get full text
    Article
  5. 605
  6. 606

    Activation of MEK1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell Lymphoma by Xintao Jia, Qiuyu He, Mei Zeng, Yuhua Chen, Yan Liu

    Published 2021-01-01
    “…Epstein-Barr virus-latent membrane protein 1 (EBV-LMP1) was associated with lymphoma, but its specific mechanism is still controversial. …”
    Get full text
    Article
  7. 607
  8. 608
  9. 609

    Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin’s lymphoma via CCR7/ARHGAP18/IKBα signaling activation by Yangyang Wang, Fan Wu, Yang Wan, Huiping Wang, Linhui Hu, Qianshan Tao, Zhimin Zhai, Jiyu Wang, Keke Huang, Anwen Ren, Jinlan Li, Liuying Yi, Yanjie Ruan, Zhixiang Wanyan, Chaohong Liu

    Published 2025-01-01
    “…Background Resistance to existing therapies is a major cause of treatment failure in patients with refractory and relapsed B-cell non-Hodgkin’s lymphoma (r/r B-NHL). Therapy-induced senescence (TIS) is one of the most important mechanisms of drug resistance.Methods This study used single-cell RNA sequencing to analyze doxorubicin-induced senescent B-NHL cells. …”
    Get full text
    Article
  10. 610

    Case report: From misdiagnosis to timely detection: a clinical and imaging guide to neurological presentations of diffuse large B-cell lymphoma—insights from six cases by Chunxiao Yang, Zihua Gong, Tao Wang, Huijuan Yuan, Weinan Na, Wei Xie, Shengyuan Yu

    Published 2025-02-01
    “…BackgroundThe clinical spectrum of diffuse large B-cell lymphoma (DLBCL) is notably heterogeneous. Some DLBCL patients initially present with neurological manifestations, leading to their preliminary diagnosis within neurology departments. …”
    Get full text
    Article
  11. 611
  12. 612
  13. 613
  14. 614
  15. 615

    Refining prognostic assessment of diffuse large B-cell lymphoma: insights from multi-omics and single-cell analysis unveil SRM as a key target for regulating immunotherapy by Xiaojie Liang, Jia Guo, Baiwei Luo, Weixiang Lu, Qiumin Chen, Yeling Deng, Yunong Yang, Liang Wang

    Published 2025-01-01
    “…HPSI shared malignant proliferative phenotype resembling Burkitt lymphoma. Genomic analysis revealed extensive copy-number loss in the chemokine and interleukin coding regions within HPSI. …”
    Get full text
    Article
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620